From GlobeNewswire: 2025-04-07 06:58:00

Pharvaris has achieved target enrollment in the RAPIDe-3 Phase 3 study for deucrictibant, strengthening confidence in clinical timelines. Enrollment for the CHAPTER-3 study is ongoing for prophylaxis of HAE attacks, with topline data expected in 2H2026. Deucrictibant has been granted orphan medicinal product designation in Europe for bradykinin-mediated angioedema treatment.

Recent data presentations highlight deucrictibant’s ability to reduce attack rates in long-term prophylaxis and effectively treat HAE attacks, including upper-airway attacks. Pharvaris maintains a strong financial position with €281 million in cash and cash equivalents as of December 31, 2024. The company is focused on developing robust clinical data to support the potential impact of deucrictibant for those with bradykinin-mediated angioedema.

Pharvaris is developing deucrictibant, a novel oral bradykinin B2 receptor antagonist, for the prevention and treatment of bradykinin-mediated angioedema attacks. The company is actively enrolling participants in pivotal Phase 3 studies for both on-demand and prophylactic treatment of HAE attacks. Recent data presentations have underscored the value of deucrictibant in long-term prophylaxis and rapid treatment of HAE attacks.

Pharvaris has been granted orphan drug designation in Europe and the U.S. for deucrictibant in the treatment of bradykinin-mediated angioedema. The company’s upcoming investor events include participation in the Citizens JMP Life Sciences Conference and Bank of America Global Healthcare Conference in May 2025. Financially, Pharvaris reported €281 million in cash and cash equivalents as of December 31, 2024, with ongoing investment in research and development to advance deucrictibant.



Read more at GlobeNewswire:: Pharvaris Reports Fourth Quarter and Full Year 2024